These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 9205742

  • 21. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
    Gabryelewicz A, Czajkowski A, Skrodzka D, Marlicz K, Luca de Tena F, Aldeguer M, Chantar C, Márquez M, Torres J, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
    Frías J, Esteban C, Carcas AJ, Sánchez-García P, Albet C, Torres J, Márquez M, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
    [Abstract] [Full Text] [Related]

  • 23. Effects of the novel histamine H2-receptor antagonist (+/-)-(E)-1-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-[2-[[[5- (methylamino)methyl-2-furyl]methyl]thio]ethyl]-2-(methylsulfonyl) guanidine on gastric secretion and gastroduodenal ulcers in rats.
    Amagase K, Kato S, Yamamoto H, Okabe S.
    Arzneimittelforschung; 1996 Feb; 46(2):177-84. PubMed ID: 8720310
    [Abstract] [Full Text] [Related]

  • 24. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
    Martínez C, Albet C, Agúndez JA, Herrero E, Carrillo JA, Márquez M, Benítez J, Ortiz JA.
    Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
    [Abstract] [Full Text] [Related]

  • 25. Carcinogenicity studies on ebrotidine.
    Romero A, Rives A, Grau MT, Villamayor F, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):515-9. PubMed ID: 9205755
    [Abstract] [Full Text] [Related]

  • 26. In vitro anti-Helicobacter pylori activity of ebrotidine.
    Palacín C, Tarragó C, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):471-4. PubMed ID: 9205746
    [Abstract] [Full Text] [Related]

  • 27. Acute toxicity studies of ebrotidine.
    Grau MT, Romero A, Villamayor F, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):490-1. PubMed ID: 9205750
    [Abstract] [Full Text] [Related]

  • 28. Chronic toxicity of ebrotidine in rats and dogs.
    Romero A, Grau MT, Villamayor F, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):498-504. PubMed ID: 9205752
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of ebrotidine and ranitidine in the treatment of benign gastric ulcer.
    Gedliczka O, Bobrzynski A, Rembiasz K, Fillat O, Torres J, Herrero E, Márquez M, Camps F, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):560-4. PubMed ID: 9205765
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of ebrotidine in rats and dogs.
    Albet C, Pérez JA, Sacristán A, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
    [Abstract] [Full Text] [Related]

  • 31. Ebrotidine versus ranitidine in the healing and prevention of relapse of duodenal ulcer. A multicentre, double-blind, parallel, randomized, controlled study.
    Tulassay Z, Döbrönte Z, Farkas I, Juhász L, Simon L, Prónai L, Torres J, Márquez M.
    Arzneimittelforschung; 1997 Apr; 47(4A):551-5. PubMed ID: 9205763
    [Abstract] [Full Text] [Related]

  • 32. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
    Slomiany BL, Piotrowski J, Murty VL, Slomiany A.
    Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
    [Abstract] [Full Text] [Related]

  • 33. The antisecretory profile of action of the H2-receptor antagonists, famotidine, loxtidine, ranitidine and L-643,441 on the rat isolated gastric mucosa.
    Reeves JJ, Stables R.
    Agents Actions; 1987 Feb; 20(1-2):22-8. PubMed ID: 2883848
    [Abstract] [Full Text] [Related]

  • 34. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
    Farré M, Roset PN, Badenas JM, Ugena B, Márquez M, Albet C, Herrero E, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
    Albet C, Pérez JA, Rozman E, Márquez M, Herrero E, Ortiz JA.
    Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
    [Abstract] [Full Text] [Related]

  • 36. Effects of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy]propyl] urea with potent gastric mucosal protective activity on acute gastric lesions and duodenal ulcers in rats.
    Sekiguchi H, Hamada K, Taga F, Nishino K.
    Arzneimittelforschung; 1993 Feb; 43(2):134-8. PubMed ID: 8096133
    [Abstract] [Full Text] [Related]

  • 37. Endothelin-1, interleukin-4 and nitric oxide synthase modulators of gastric mucosal injury by indomethacin: effect of antiulcer agents.
    Slomiany BL, Piotrowski J, Slomiany A.
    J Physiol Pharmacol; 1999 Jun; 50(2):197-210. PubMed ID: 10424717
    [Abstract] [Full Text] [Related]

  • 38. Protective effect of roxatidine against indomethacin-induced small intestinal mucosal injury in rats.
    Umegaki E, Yoda Y, Tokioka S, Murano M, Higuchi K.
    J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S35-40. PubMed ID: 20586863
    [Abstract] [Full Text] [Related]

  • 39. Gastroprotective and antisecretory effects of ebrotidine.
    Konturek SJ, Maczka J, Kaminski K, Sito E, Torres J, Oleksy J.
    Scand J Gastroenterol; 1992 Jun; 27(6):438-42. PubMed ID: 1352908
    [Abstract] [Full Text] [Related]

  • 40. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
    Slomiany BL, Piotrowski J, Slomiany A.
    J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.